{Stature QTL 7} (2), STQTL7
{Asthma, aspirin-induced, susceptibility to}, 208550 (3), PTGER2
HMG-CoA lyase deficiency, 246450 (3), HMGCL
Histiocytoma, angiomatoid fibrous, somatic, 612160 (3), CREB1
{Stature QTL 1} (2), STQTL1
?Thrombocytopenia, Paris-Trousseau type (4), TCPT
Acropectorovertebral dysplasia (2), ACRPV
?Sertoli-cell-only syndrome (1), DAZ
Hypermethioninemia due to adenosine kinase deficiency, 614300 (3), ADK
{Major affective disorder 5} (2), MAFD5
Trehalase deficiency, 612119 (1), TREH
Infections, recurrent, with encephalopathy, hepatic dysfunction,, FADD
Mitochondrial complex II deficiency, 252011 (3), SDHAF1
?{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3), NEFH
Alzheimer disease-11 (2), AD11
Myotonia congenita, recessive, 255700 (3); Myotonia congenita,, CLCN1
Combined malonic and methylmalonic aciduria, 614265 (3), ACSF3
Mental retardation syndrome, X-linked, Armfield type (2), MRXSA
Myopathy, distal 3 (2), MPD3
Norum disease, 245900 (3); Fish-eye disease, 136120 (3), LCAT
Small patella syndrome, 147891 (3), TBX4
Spinocerebellar ataxia 37 (2), SCA37
Preauricular tag, isolated, autosomal dominant, 1 (2), PAURT1
{Patent ductus arteriosus, susceptibility to} (2), PDA1
[QT interval, variation in] (2), QTV
?Roifman-Chitayat syndrome (2), RCHTS
Cubitus valgus with mental retardation and unusual facies (2), CVMRF
Otosclerosis 5 (2), OTSC5
{Tuberculosis, susceptibility to} (2), MTBS1
{Systemic lupus erythematosus, susceptibility to, 12} (2), SLEB12
{Stature QTL 4} (2), STQTL4
[Social cognition] (2), CGF1
{Colorectal cancer, susceptibility to, 6} (2), CRCS6
Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 (3), ITGA7
Developmental dysplasia of the hip 2 (2), DDH2
[Body mass index QTL5] (2), BMIQ5
Optic atrophy 4 (2), OPA4
Dystonia, myoclonic, 159900 (3), DRD2
{Neuroblastoma, susceptibility to, 6} (2), NBLST6
Leukemia, acute promyelocytic, NUMA/RARA type (3), NUMA1
Colorectal cancer, somatic (3), DLC1
Corneal dystrophy, Lisch epithelial (2), LECD
Hyperinsulinism-hyperammonemia syndrome, 606762 (3), GLUD1
{Rheumatoid arthritis, susceptibility to} (2), RA
Microcephaly 1, primary, autosomal recessive, 251200 (3), MCPH1
Mental retardation, X-linked 78 (2), MRX78
Synesthesia (2), SYNSTH
Deafness, autosomal dominant 16 (2), DFNA16
{Epilepsy, idiopathic generalized, susceptibility to, 1} (2), EIG1
Leukemia-2, T-cell acute lymphoblastic (3), TAL2
{Hypersensitivity syndrome, carbamazepine-induced, susceptibility, HLA-A
[Bone mineral density QTL 5] (2), BMND5
{Inflammatory bowel disease 11} (2), IBD11
Postaxial polydactyly, type A2 (2), PAPA2
Methylmalonic aciduria and homocystinuria, cblC type, 277400 (3), MMACHC
Mental retardation, X-linked 81 (2), MRX81
{Asthma-related traits, susceptibility to, 3} (2), ASRT3
Glaucoma 1, open angle, I (2), GLC1I
{Obesity, severe, and type II diabetes}, 601665 (3), UCP3
Hyperlysinemia, 238700 (3); Saccharopinuria, 268700 (1), AASS
{Gilles de la Tourette syndrome, susceptibility to}, 137580 (3), HDC
{Basal cell carcinoma, susceptibility to, 6} (2), BCC6
Acatalasemia, 614097 (3), CAT
Gustavson syndrome (2), GUST
Cerebral palsy, ataxic, autosomal recessive (2), ACP
Epilepsy, familial temporal lobe, 6 (2), ETL6
{Hepatic fibrosis susceptibility due to Schistosoma mansoni, SM2
Lymphedema, hereditary, IB (2), LMPH1B
{Scoliosis, idiopathic, susceptibility to, 5} (2), IS5
{Inflammatory bowel disease 27} (2), IBD27
{Psoriasis susceptibility 7} (2), PSORS7
{Inflammatory bowel disease 20} (2), IBD20
{Alcohol dependence, susceptibility to}, 103780 (3), GABRA2
Exudative vitreoretinopathy 3 (2), EVR3
Spastic paraplegia, optic atrophy, and neuropathy (2), SPOAN
Thyroxine-binding globulin deficiency (3), TBG
Deafness, autosomal recessive 65 (2), DFNB65
Orofacial cleft 4 (2), OFC4
Cerebral-cerebellar-coloboma syndrome, X-linked (2), CCCSX
Goiter, multinodular, 2 (2), MNG2
?ACAT2 deficiency, 614055 (1), ACAT2
Hermansky-Pudlak syndrome 3, 614072 (3), HPS3
{Glioma susceptibility 4} (2), GLM4
?Hyperimmunoglobulin G1 syndrome (2), IGHR
[Hematocrit/hemoglobin quantitative trait locus 2] (2), HCHGQ2
[Mean platelet volume QTL1] (2), MPVQTL1
{Basal cell carcinoma, susceptibility to, 5} (2), BCC5
Polycystic kidney disease, infantile severe, with tuberous sclerosis, PKDTS
Argininemia, 207800 (3), ARG1
Hermansky-Pudlak syndrome 4, 614073 (3), HPS4
{Stature QTL 9} (2), STQTL9
Episodic kinesigenic dyskinesia 2 (2), EKD2
Dupuytren contracture 1 (2), DUPC1
Stuttering, familial persistent, 2 (2), STUT2
Neurofibrosarcoma (3);, MXI1
Nystagmus 5, congenital, X-linked (2), NYS5
Emanuel syndrome (4), DER22t11-22
{Basal cell carcinoma, susceptibility to, 3} (2), BCC3
[Erythrocytosis, familial, 1], 133100 (3), EPOR
Usher syndrome, type IK (2), USH1K
Aortic aneurysm, familial abdominal 2 (2), AAA2
Deafness, autosomal recessive 40 (2), DFNB40
{IgA nephropathy, susceptibility to, 1} (2), IGAN1
Charcot-Marie-Tooth disease, axonal, type 2G (2), CMT2G
Mental retardation, X-linked 73 (2), MRX73
Dysplasminogenemia, 217090 (3); Plasminogen deficiency, type I,, PLG
Hyperbiliverdinemia, 614156 (3), BLVRA
Senior-Loken syndrome 3 (2), SLSN3
Spiegler-Brooke syndrome (2), SBS
Alopecia areata 1 (2), AA1
?Leigh syndrome, 256000 (3), NDUFA10
Growth retardation, developmental delay, coarse facies, and early, FTO
{Psoriasis susceptibility 10} (2), PSORS10
Leukemia, Philadelphia chromosome-positive, resistant to imatinib (3), ABL1
{Lung cancer susceptibility 5} (2), LNCR5
Microphthalmia, isolated 1 (2), MCOP1
[Thyroid-stimulating hormone level QTL 1] (2), TSHQTL1
{Autism susceptibility 3} (2), AUTS3
Macrocephaly with multiple epiphyseal dysplasia and distinctive, MMEDF
Mental retardation, X-linked 88 (2), MRX88
Glycogen storage disease VI, 232700 (3), PYGL
Spinal muscular atrophy, chronic distal, autosomal recessive (2), SMAR
Supernumerary der(22)t(8-22) syndrome (4), DER22t8-22
Roberts syndrome, 268300 (3); SC phocomelia syndrome, 269000 (3), ESCO2
Aneurysm, intracranial berry, 3 (2), ANIB3
[Superoxide dismutase, elevated extracellular] (3), SOD3
{Stature QTL 2} (2), STQTL2
Episodic ataxia, type 8 (2), EA8
Spinocerebellar ataxia 4 (2), SCA4
{Malignant hyperthermia susceptibility 2} (2), MHS2
Acropectoral syndrome (2), ACRPS
{Autism susceptibility 5} (2), AUTS5
[Bone mineral density QTL 11] (2), BMND11
MHC class II deficiency, complementation group B, 209920 (3), RFXANK
Epilepsy, hot water, 2 (2), HWE2
Deafness, autosomal recessive 38 (2), DFNB38
Basal ganglia calcification, idiopathic, 2 (2), IBGC2
{Colorectal cancer, susceptibility to, 9} (2), CRCS9
Deafness, autosomal dominant 59 (2), DFNA59
{Asthma, nocturnal, susceptibility to}, 600807 (3); {Obesity,, ADRB2
Cervical carcinoma (2), ST3
{Ovarian cancer, somatic}, 167000 (3), OPCML
Chronic granulomatous disease due to deficiency of NCF-2, 233710 (3), NCF2
{Ovarian cancer, susceptibility to} (2), OVCAS1
Supranuclear palsy, progressive, 3 (2), PSNP3
Neuropathy, hereditary sensory, type IB (2), HSN1B
Roifman syndrome (2), RFMN
Cavitary optic disc anomalies (2), CODA
Arrhythmogenic right ventricular dysplasia 6 (2), ARVD6
Episodic muscle weakness, X-linked (2), EMWX
{Alzheimer disease-13} (2), AD13
[Ezetimibe, nonresponse to] (3), NPC1L1
Deafness, autosomal dominant 27 (2), DFNA27
{Age-related hearing impairment 1} (2), ARHI1
Holoprosencephaly-1 (2), HPE1
?Anal canal carcinoma (2), ANC
Brooks-Wisniewski-Brown syndrome (2), MRXSBWB
{Multiple sclerosis, susceptibility to, 3} (2), MS3
Deafness, Y-linked 1 (1), DFNY1
Ehlers-Danlos syndrome, type VIIB, 130060 (3); Osteogenesis, COL1A2
Meningioma, radiation-induced (2), MNRI
Dyserythropoietic anemia, congenital, type Ib, 615631 (3), C15orf41
Ventricular tachycardia, catecholaminergic polymorphic, 3 (2), CPVT3
[Bone mineral density QTL 14] (2), BMND14
Porphyria cutanea tarda, 176100 (3); Porphyria, hepatoerythropoietic,, UROD
Myopia 9 (2), MYP9
{Hypertriglyceridemia, susceptibility to}, 145750 (3);, APOA5
Dyskeratosis, hereditary benign intraepithelial (2), DKBI
{Inflammatory bowel disease 21} (2), IBD21
[Blood group, OK], 111380 (3), BSG
Glycosylphosphatidylinositol deficiency, 610293 (3), PIGM
Deafness, autosomal dominant 5, 600994 (3), DFNA5
Galactose epimerase deficiency, 230350 (3), GALE
Rickets due to defect in vitamin D 25-hydroxylation, 600081 (3), CYP2R1
46XX sex reversal 3 (4), SRXX3
{Migraine with or without aura, susceptibility to, 5} (2), MGR5
Mental retardation, X-linked 23 (2), MRX23
Febrile seizures, familial, 10 (2), FEB10
Glaucoma 1, open angle, H (2), GLC1H
[Skin/hair/eye pigmentation 11, blue/nonblue eyes] (2), SHEP11
[Fructosuria], 229800 (3), KHK
{Diabetes mellitus, noninsulin-dependent}, 125853 (3); {Coronary, IRS1
Periventricular nodular heterotopia 3 (2), PVNH3
Tyrosinemia, type I, 276700 (3), FAH
{Colorectal cancer, susceptibility to, 11} (2), CRCS11
Deafness, neurosensory, autosomal recessive 47 (2), DFNB47
{Coronary heart disease, susceptibility to, 9} (2), CHDS9
Neutropenia, neonatal alloimmune (1), LAG5
Mental retardation, X-linked 92 (2), MRX92
Mean platelet volume QTL5 (2), MPVQTL5
{Colorectal cancer, susceptibility to, 7} (2), CRCS7
Gallbladder disease 3 (2), GBD3
Retinitis pigmentosa 2, 312600 (3), RP2
{Prostate cancer, susceptibility to, 4}, 176807 (2), HPC4
Charcot-Marie-Tooth disease, axonal, type 2H (2), CMT2H
Deafness, autosomal recessive 85 (2), DFNB85
{Atherosclerosis, susceptibility to} (3); {Asthma, diminished, ALOX5
Bare lymphocyte syndrome, type II, complementation group C, 209920, RFX5
Supravalvar aortic stenosis, 185500 (3); Cutis laxa, AD, 123700 (3), ELN
Hemolytic anemia due to glutathione reductase deficiency (1), GSR
Hyperphenylalaninemia, BH4-deficient, A, 261640 (3), PTS
{Stature QTL 23} (2), STQTL23
Myopia 13 (2), MYP13
Adrenocorticotropic hormone deficiency, 201400 (3), TBX19
{Aneurysm, intracranial berry, 6} (2), ANIB6
Adenylosuccinase deficiency, 103050 (3), ADSL
Pyloric stenosis, infantile hypertrophic, 3 (2), IHPS3
Mental retardation, X-linked 53 (2), MRX53
{Hypertension, essential, susceptibility to, 8} (2), HYT8
{Leber optic atrophy, susceptibility to} (2), LOAS
Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 (3), CASQ2
Li-Fraumeni syndrome 3 (2), LFS3
Progressive familial heart block, type II (2), PFHB2
{Migraine, with or without aura, susceptibility to, 12} (2), MGR12
{Attention deficit-hyperactivity disorder, susceptibility to, 5} (2), ADHD5
Hirschsprung disease, cardiac defects, and autonomic dysfunction,, ECE1
[Blood group, Kell], 110900 (3), KEL
{Malignant hyperthermia susceptibility 6} (2), MHS6
Deafness, autosomal recessive 5 (2), DFNB5
Antley-Bixler syndrome with genital anomalies and disordered, POR
Panic disorder syndrome 1 (2), PAND1
Pigment disorder, reticulate (2), PDR
Muscular dystrophy, limb-girdle, type 1H (2), LGMD1H
Aneurysm, intracranial berry, 8 (2), ANIB8
{?Membranous nephropathy, susceptibility to} (2), MBNP
Potocki-Lupski syndrome (4), PTLS
Alopecia areata 2 (2), AA2
Carotid intimal medial thickness (2), CIMT
Methylmalonic aciduria, vitamin B12-responsive, 251100 (3), MMAA
Hashimoto thyroiditis (2), HT
{Hirschsprung disease, susceptibility to, 9} (2), HSCR9
Homocystinuria-megaloblastic anemia, cbl E type, 236270 (3);, MTRR
{T-cell acute lymphoblastic leukemia} (3), MYB
Myopia 20, autosomal dominant (2), MYP20
Deafness, autosomal recessive 14 (2), DFNB14
{Hirschsprung disease, susceptibility to, 8} (2), HSCR8
{Prostate cancer, hereditary, 9} (2), HPC9
[Body mass index QTL 15] (2), BMIQ15
[Bone mineral density QTL 9] (2), BMND9
[Bone mineral density QTL 4] (2), BMND4
{Restless legs syndrome 1} (2), RLS1
Ectodermal dysplasia 8, hair/tooth/nail type (2), ECTD8
Homocystinuria due to MTHFR deficiency, 236250 (3); {Schizophrenia,, MTHFR
Optic atrophy 2, X-linked (2), OPA2
Hemolytic anemia due to adenylate kinase deficiency, 612631 (3), AK1
Keratoconus 5 (2), KTCN5
{Stature QTL 13} (2), STQTL13
{Influenza, severe, susceptibility to}, 614680 (3), IFITM3
{Prostate cancer, progression of}, 176807 (1), HIP1
{Prostate cancer, hereditary, 7} (2), HPC7
Glutaricaciduria, type I, 231670 (3), GCDH
Supranuclear palsy, progressive, 2 (2), PSNP2
[Body mass index QTL13] (2), BMIQ13
Glaucoma 1B, primary open angle, adult onset, (2), GLC1B
{Mental health wellness-1} (2), MHW1
Friedreich ataxia 2 (2), FRDA2
Bardet-Biedl syndrome 4, 615982 (3), BBS4
Spastic paraplegia 24, autosomal recessive (2), SPG24
Thyrotropin-releasing hormone deficiency, 275120 (1), TRH
Holoprosencephaly-6 (2), HPE6
?Spinocerebellar ataxia 30 (2), SCA30
{Autism susceptibility 8} (2), AUTS8
Telangiectasia, hereditary benign (2), HBT
{Aneurysm, intracranial berry, 9} (2), ANIB9
{Spondyloarthropathy, susceptibility to, 3} (2), SPDA3
Myoclonic epilepsy, juvenile, 4 (2), EJM4
{Diabetes mellitus, insulin-dependent, 19} (2), IDDM19
{Dermatitis, atopic, susceptibility to, 3} (2), ATOD3
Epilepsy, hot water, 1 (2), HWE1
Retinitis pigmentosa 24 (2), RP24
Alzheimer disease-10, 104300 (2), AD10
Lymphoma, non-Hodgkin, somatic, 605027 (3); Colon cancer, somatic,, RAD54B
Glutamate formiminotransferase deficiency, 229100 (3), FTCD
Factor VII deficiency, 227500 (3); {Myocardial infarction,, F7
Deafness, autosomal recessive 27 (2), DFNB27
{Glioma susceptibility 8} (2), GLM8
Biotinidase deficiency, 253260 (3), BTD
Specific language impairment QTL, 2 (2), SLI2
Deafness, autosomal dominant 24 (2), DFNA24
Myopathy, congenital, with fiber-type disproportion, X-linked (2), CFTDX
{Restless legs syndrome 6} (2), RLS6
{Age-related hearing impairment 2} (2), ARHI2
[Longevity 1] (2), LGV1
{Migraine with aura, susceptibility to, 7} (2), MGR7
Mitral valve prolapse, myxomatous 3 (2), MMVP3
Sucrase-isomaltase deficiency, congenital, 222900 (3), SI
{Hypertension, essential, susceptibility to, 2}, 145500 (2), HYT2
{Prostate cancer, susceptibility to, 3}, 176807 (2), HPC3
Cleft palate, isolated, 119540 (2), UBB
Febrile seizures, familial, 2 (2), FEB2
{Autoimmune thyroid disease, susceptibility to, 2} (2), AITD2
[Musical aptitude QTL 1] (2), MUSQTL1
{Melanoma, cutaneous malignant, 4} (2), CMM4
{Alzheimer disease-14} (2), AD14
Rippling muscle disease-1 (2), RMD1
Total anomalous pulmonary venous return (2), TAPVR1
{Autoimmune thyroid disease, susceptibility to, 4} (2), AITD4
GM2-gangliosidosis, AB variant, 272750 (3), GM2A
Leigh syndrome due to mitochondrial complex I deficiency, 256000, NDUFA9
Myopia 5 (2), MYP5
Breast cancer, 11:22 translocation associated (1), BRCATA
Esophageal carcinoma, somatic, 133239 (3), RNF6
Ciliary dyskinesia, primary, 4 (2), CILD4
Hypotrichosis 10 (2), HYPT10
{Celiac disease, susceptibility to, 13} (2), CELIAC13
{Dermatitis, atopic, susceptibility to, 5} (2), ATOD5
{Diabetes mellitus, insulin-dependent, X-linked} (2), IDDMX
{Leukemia, acute lymphocytic, susceptibility to, 1} (2), ALL1
Cardiomyopathy, dilated, 1K (2), CMD1K
Alzheimer disease 17 (2), AD17
Myopia-3 (2), MYP3
Ehlers-Danlos syndrome, type IV, 130050 (3); Ehlers-Danlos syndrome,, COL3A1
Lung cancer, 211980 (3), PPP2R1B
Preeclampsia/eclampsia 3 (2), PEE3
Stuttering, familial persistent, 3 (2), STUT3
{Psoriasis susceptibility 3} (2), PSORS3
{Celiac disease, susceptibility to, 9} (2), CELIAC9
Myopia-2 (2), MYP2
Joubert syndrome-3, 608629 (3), AHI1
Atrial fibrillation, familial, 2 (2), ATFB2
C8 deficiency, type II, 613789 (3), C8B
Dowling-Degos disease 3 (2), DDD3
Phobia, specific (2), PHOBS
Mitral valve prolapse, myxomatous 2 (2), MMVP2
{Specific language impairment 4} (2), SLI4
{Asthma, protection against}, 600807 (3), MUC7
Cone-rod dystrophy 8 (2), CORD8
OKT4 epitope deficiency, 613949 (3), CD4
[Mean platelet volume QTL2] (2), MPVQTL2
Deafness, autosomal recessive 62 (2), DFNB62
Moyamoya disease 3 (2), MYMY3
{High density lipoprotein cholesterol, low serum, 3} (2), HDLC3
Glomerulopathy with fibronectin deposits 1 (2), GFND1
Aneurysm, intracranial berry, 5 (2), ANIB5
?Laryngeal adductor paralysis (2), LAP
[Hematocrit/hemoglobin quantitative trait locus 3] (2), HCHGQ3
Thyrotropin-releasing hormone resistance, generalized (3), TRHR
Photoparoxysmal response 1 (2), PPR1
{Malaria, cerebral, susceptibility to}, 611162 (3), ICAM1
{Glioma, susceptibility to, somatic}, 137800 (3), IDH1
Mental retardation, X-linked 20 (2), MRX20
{Epilepsy, idiopathic generalized, susceptibility to, 5} (2), EIG5
Polydactyly, postaxial, type A4 (2), PAPA4
{Stature QTL 8} (2), STQTL8
{Leukemia, chronic lymphocytic, susceptibility to, 3} (2), CLLS3
Zygodactyly 1 (2), ZD1
Tolbutamide poor metabolizer (3); Warfarin sensitivity, 122700 (3), CYP2C9
Mitochondrial complex IV deficiency, 220110 (3); Leigh syndrome, COX10
Epilepsy, rolandic, with paroxysmal exercise-induced dystonia and, EPRPDC
Hyperlipoproteinemia, type Ib, 207750 (3), APOC2
Neutrophil immunodeficiency syndrome, 608203 (3), RAC2
Alzheimer disease-5, 104300 (2), AD5
Ectodermal dysplasia/skin fragility syndrome, 604536 (3), PKP1
Cardiomyopathy, familial restrictive, 2 (2), RCM2
{Stature QTL 18} (2), STQTL18
Chromosome 2q31.2 deletion syndrome (4), DEL2q31
Hypoparathyroidism, autosomal dominant, 146200 (3);, PTH
{Asthma, susceptibility to}, 600807 (2), HLA-G
Albinism, oculocutaneous, type V (2), OCA5
Fetal hemoglobin quantitative trait locus 1, 141749 (3), HBG1
Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 (3);, CYP11B2
?Spastic paraplegia 41, autosomal dominant (2), SPG41
{Bladder cancer, somatic}, 109800 (3); Costello syndrome, 218040 (3);, HRAS
[Hypoceruloplasminemia, hereditary], 604290 (3);, CP
Retinitis pigmentosa 63 (2), RP63
[Longevity 2] (2), LGV2
Camptodactyly 1 (2), CAMPD1
{Diabetes mellitus, insulin-dependent, 24} (2), IDDM24
Exostoses, multiple, type 2, 133701 (3), EXT2
{Autism susceptibility 1} (2), AUTS1
Occult macular dystrophy, 613587 (3), RP1L1
Orofacial cleft 13 (2), OFC13
Leukemia, acute lymphoblastic (2), LALL
{Alzheimer disease-15} (2), AD15
Paroxysmal nonkinesigenic dyskinesia 2 (2), PNKD2
Porokeratosis 7 (2), POROK7
Ectodermal dysplasia 5, hair/nail type (2), ECTD5
Biliary cirrhosis, primary, 1 (2), PBC1
Mental retardation, autosomal recessive 24 (2), MRT24
Split-hand/foot malformation with long bone deficiency 2 (2), SHFLD2
Nanophthalmos-1 (2), NNO1
{Lumbar disc herniation, susceptibility to}, 603932 (3), THBS2
{Autism susceptibility 6} (2), AUTS6
[Telomere length, mean leukocyte] (2), TELM
{Celiac disease, susceptibility to, 2} (2), CELIAC2
Mental retardation, X-linked syndromic 7 (2), MRXS7
Bardet-Biedl syndrome 1, 209900 (3), BBS1
Hypophosphatemic rickets and hyperparathyroidism (2), HPRHP
{IgA nephropathy, susceptibility to, 2} (2), IGAN2
Aplasia of lacrimal and salivary glands, 180920 (3); LADD syndrome,, FGF10
Glycerol kinase deficiency, 307030 (3), GK
Febrile seizures, familial, 7 (2), FEB7
{Inflammatory bowel disease 2} (2), IBD2
Deafness, autosomal recessive 32 (2), DFNB32
{Hirschsprung disease, susceptibility to, 5} (2), HSCR5
Enuresis, nocturnal, 1 (2), ENUR1
Esophageal squamous cell carcinoma, 133239 (1), DEC1
Mental retardation, autosomal recessive 32 (2), MRT32
{Schizophrenia, susceptibility to}, 181500 (3); {Obsessive-compulsive, HTR2A
C6 deficiency, 612446 (3); Combined C6/C7 deficiency (3), C6
Mental retardation, autosomal recessive, 11 (2), MRT11
{Human herpesvirus 8, susceptibility to} (2), HHV8S
Somatostatin analog, resistance to (3), SSTR5
Lung cancer, 211980 (2), RASSF1
{Basal cell carcinoma, susceptibility to, 1} (2), BCC1
{Systemic lupus erythematosus, susceptibility to, 3} (2), SLEB3
[Bone mineral density QTL 13] (2), BMND13
[Polyunsaturated fatty acids plasma level QTL1] (2), PURAQTL1
{Migraine with or without aura, susceptibility to, 3} (2), MGR3
Fructose-1,6-bisphosphatase deficiency, 229700 (3), FBP1
{Alkaline phosphatase, plasma level of, QTL3} (2), ALPQTL3
[Hematocrit/hemoglobin quantitative trait locus 1] (2), HCHGQ1
{?Hearing loss, cisplatin-induced, susceptibility to} (2), CIHL
Bornholm eye disease (2), BED
Keratoconus 3 (2), KTCN3
{Migraine, susceptibility to, 8} (2), MGR8
Pulmonary alveolar microlithiasis, 265100 (3); ?Testicular, SLC34A2
Tyrosinemia, type II, 276600 (3), TAT
Muscle strength quantitative trait locus 1 (2), MUSTQTL1
Thalassemia, Hispanic gamma-delta-beta, 613985 (3), LCRB
{Colonic adenoma recurrence, reduced risk of}, 114500 (3), ODC1
[Body mass index QTL3] (2), BMIQ3
?Male infertility due to acrosin deficiency (2), ACR
Leukemia, acute promyelocytic, 612376 (1), RARA
Mental retardation, X-linked syndromic, Abidi type (2), MRXSAB
Epilepsy, nocturnal frontal lobe, type 4, 610353 (3), CHRNA2
{Alzheimer disease 16} (2), AD16
{Esophagitis, eosinophilic, 2} (2), EOE2
Leukemia, acute myeloid, reduced survival in, 601626 (3); Leukemia,, FLT3
Rickets, vitamin D-resistant, type IIA, 277440 (3);, VDR
{?Allergy and asthma susceptibility} (2), IGES
Kyphoscoliosis 1 (2), KYPSC1
Pyloric stenosis, infantile hypertrophic, 2 (2), IHPS2
Pelviureteric junction obstruction (2), PUJO
{Gastric cancer risk after H. pylori infection}, 137215 (3), IL1B
[Inosine triphosphatase deficiency], 613850 (3), ITPA
Apolipoprotein A-II deficiency (3); {Hypercholesterolemia, familial,, APOA2
{Smoking as a quantitative trait locus 2} (2), SQTL2
{Autism susceptibility 4} (2), AUTS4
[High density lipoprotein cholesterol level QTL 2] (2), HDLCQ2
Keutel syndrome, 245150 (3), MGP
{Malignant hyperthermia susceptibility 4} (2), MHS4
Myopia 11 (2), MYP11
Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal, FBLN1
{Drug addiction, susceptibility to}, 606581 (3), FAAH
Cholangitis, primary sclerosing (2), PSC
Syncope, familial vasovagal (2), VVS
Atrial septal defect 1 (2), ASD1
Cardiomyopathy, hypertrophic, 21 (2), CMH21
Coproporphyria, 121300 (3); Harderoporphyria, 121300 (3), CPOX
?Ragweed sensitivity (2), RWS
Atrial fibrillation, familial, 1 (2), ATFB1
Abetalipoproteinemia, 200100 (3); {Metabolic syndrome, protection, MTP
{Follicular lymphoma, susceptibility to, 1} (2), FL1
{Hypertension, essential, susceptibility to, 7} (2), HYT7
{Alkaline phosphatase, plasma level of, QTL1} (2), ALPQTL1
Leukoencephalopathy with metaphyseal chondrodysplasia (2), LKMCD
Mental retardation, X-linked 82 (2), MRX82
Colorectal cancer with chromosomal instability, somatic (3), BUB1
Myopia 18 (2), MYP18
Keratoconus 4 (2), KTCN4
Creatinine clearance QTL (2), CRCL
IgG2 deficiency, selective (3), IGHG2
Alopecia, androgenetic, 3 (2), AGA3
DNA ligase I deficiency (3), LIG1
Dermatitis, atopic, 8 (2), ATOD8
?Hydrocephalus, autosomal dominant (2), HDCPH1
Pallister-Killian syndrome (4), PKS
FG syndrome 3 (2), FGS3
{Inflammatory bowel disease 26} (2), IBD26
Colorectal cancer, somatic, 114500 (3), MCC
Diabetes insipidus, nephrogenic, 125800 (3), AQP2
{Celiac disease, susceptibility to, 10} (2), CELIAC10
Schizophrenia, 181500 (2), DISC2
{Inflammatory bowel disease 24} (2), IBD24
Nystagmus 4, congenital, autosomal dominant (2), NYS4
Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 (3), DDB2
?Tibial hemimelia (2), THM
Megaloblastic anemia due to dihydrofolate reductase deficiency,, DHFR
Lymphoma, B-cell (2), BCL6
Deafness, autosomal dominant 54 (2), DFNA54
C7 deficiency, 610102 (3), C7
{Meconium ileus in cystic fibrosis, susceptibility to} (2), CFM1
Sitosterolemia, 210250 (3), ABCG5
Prolidase deficiency, 170100 (3), PEPD
Vesicoureteral reflux 4 (2), VUR4
Griscelli syndrome, type 3, 609227 (3), MLPH
{Atrial fibrillation, familial, 5} (2), ATFB5
{Osteoarthritis susceptibility 6} (2), OS6
Lymphocytic leukemia, acute T-cell (3), RAP1GDS1
?Lysosomal acid phosphatase deficiency, 200950 (1), ACP2
{Hypertension, essential, susceptibility to, 6}, 145500 (2), HYT6
Hair, curly (2), HRM2
{Stature QTL 17} (2), STQTL17
{Schizophrenia, susceptibility to, 14} (2), SCZD14
Keratoconus 8 (2), KTCN8
Gastrointestinal stromal tumor, somatic, 606764 (3);, PDGFRA
{Leukemia, chronic lymphocytic susceptibility to, 4} (2), CLLS4
Orofacial cleft-3 (2), OFC3
{Chronic mountain sickness, susceptibility to} (2), CMTS
Leukemia, T-cell acute lymphoblastoid (2), LYL1
{Dermatitis, atopic, susceptibility to, 7} (2), ATOD7
{Nasopharyngeal carcinoma, susceptibility to, 2} (2), NPCA2
Dystonia-7, torsion (2), DYT7
Carney complex, type II (2), CNC2
N-acetylglutamate synthase deficiency, 237310 (3), NAGS
{Autism susceptibility 13} (2), AUTS13
Fanconi anemia, complementation group F, 603467 (3), FANCF
Arthrogryposis, distal, type 10 (2), DA10
{Systemic lupus erythematosus with hemolytic anemia} (2), SLEH1
Dermatitis, atopic, 9 (2), ATOD9
[Fetal hemoglobin QTL5] (2), HBFQTL5
{Autoimmune thyroid disease, susceptibility to, 1} (2), AITD1
Multiple endocrine neoplasia 1, 131100 (3); Carcinoid tumor of lung, MEN1
Vesicoureteral reflux (2), VUR
Epidermolysis bullosa, junctional, with pyloric stenosis, 226730, ITGA6
{Scoliosis, idiopathic, susceptibility to, 4} (2), IS4
Arrhythmogenic right ventricular dysplasia 3 (2), ARVD3
Leukotriene C4 synthase deficiency, 614037 (1), LTC4S
Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive,, SLC25A38
Hemangioma, capillary infantile, somatic, 602089 (3); {Hemangioma,, KDR
{Prostate cancer, hereditary, X-linked 2} (2), HPCX2
Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 (3), VPS33B
[?Hyperproglucagonemia] (1), GCG
Wood neuroimmunologic syndrome (2), INDX
Neuronopathy, distal hereditary motor, type I (2), DHMN1
Spastic paraplegia 27, autosomal recessive (2), SPG27
{Psoriasis susceptibility 8} (2), PSORS8
Hypercalciuria, absorptive (2), HCA1
Macular dystrophy, dominant cystoid (2), MDDC
Lacticacidemia due to PDX1 deficiency, 245349 (3), PDX1
Nystagmus 7, congenital, autosomal dominant (2), NYS7
Deafness, autosomal recessive 13 (2), DFNB13
Deafness, autosomal recessive 25, 613285 (3), GRXCR1
{Coronary heart disease, susceptibility to, 8} (2), CHDS8
{Strabismus, susceptibility to, 1} (2), STBMS1
Hypoparathyroidism, familial isolated, 146200 (3), GCMB
Alopecia-mental retardation syndrome 1 (2), APMR1
Robinow syndrome, autosomal dominant 1, 180700 (3), WNT5A
Myopia 7 (2), MYP7
Leigh syndrome due to mitochondrial complex 1 deficiency,, NDUFA12
Dystonia 13, torsion (2), DYT13
Renal hypodysplasia, nonsyndromic, 1 (2), RHDNS1
Deafness, autosomal dominant 43 (2), DFNA43
Nanophthalmos 3 (2), NNO3
HMG-CoA synthase-2 deficiency, 605911 (3), HMGCS2
Deafness, cataract, retinitis pigmentosa, and sperm abnormalities (2), DFCTRPS
Aromatic L-amino acid decarboxylase deficiency, 608643 (3), DDC
{Diabetes mellitus, insulin-dependent-1} (2), IDDM1
Episodic ataxia, type 7 (2), EA7
Tetrasomy 18p (4), TET18P
Deafness, autosomal recessive 17 (2), DFNB17
Hyperuricemic nephropathy, familial juvenile, 3 (2), HNFJ3
?Hypertrichosis universalis congenita, Ambras type (2), HTC1
Retinitis pigmentosa 34 (2), RP34
{Leprosy, paucibacillary type, susceptibility to} (2), LPRS
Fundus albipunctatus, 136880 (3); Retinitis punctata albescens,, RLBP1
Myopia 19 (2), MYP19
[Fasting plasma glucose level QTL 3] (2), FGQTL3
Diabetes mellitus, noninsulin-dependent, 2 (2), NIDDM2
Meier-Gorlin syndrome 4, 613804 (3), CDT1
{Mental health wellness-2} (2), MHW2
{Asthma-related traits, susceptibility to, 8} (2), ASRT8
Thrombocythemia, X-linked (2), THCYTX
Episodic ataxia, type 3 (2), EA3
Retinoblastoma, 180200 (3); Osteosarcoma, somatic, 259500 (3);, RB1
{Prostate cancer, hereditary, X-linked 1} (2), HPCX1
Canavan disease, 271900 (3), ASPA
Mental retardation, autosomal recessive 16 (2), MRT16
Otosclerosis 3 (2), OTSC3
Nail disorder, nonsyndromic congenital, 7 (2), NDNC7
Radial ray deficiency (2), RRDX
DNA topoisomerase I, camptothecin-resistant (3), TOP1
Stargardt disease 4 (2), STGD4
Mental retardation, autosomal recessive 23 (2), MRT23
{Hypertension, diastolic, resistance to}, 608622 (3), KCNMB1
{Autism susceptibility 12} (2), AUTS12
Radiation sensitivity/chromosome instability syndrome, autosomal, RSCIS
{Dermatitis, atopic, susceptibility to, 6} (2), ATOD6
?N syndrome, 310465 (1), POLA1
{Inflammatory bowel disease 5} (2), IBD5
Spinocerebellar ataxia, autosomal recessive with axonal neuropathy,, TDP1
3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 (3), HIBCH
Spastic paraplegia 19, autosomal dominant (2), SPG19
Chronic granulomatous disease due to deficiency of NCF-1, 233700 (3), NCF1
{Systemic lupus erythematosus, susceptibility to, 8} (2), SLEB8
Sandhoff disease, infantile, juvenile, and adult forms, 268800 (3), HEXB
{Epilepsy, idiopathic generalized, susceptibility to, 3} (2), EIG3
Macular dystrophy, butterfly-shaped pigmentary, 2 (2), MDBS2
Hyperchlorhidrosis, isolated, 143860 (3), CA12
{Stature QTL 16} (2), STQTL16
Febrile seizures, familial, 9 (2), FEB9
{Sarcoidosis, susceptibility to, 3} (2), SS3
{Prostate cancer aggressiveness QTL}, 176807 (2), HPCQTL19
Waardenburg syndrome, type 2C (2), WS2C
Alopecia, androgenetic, 2 (2), AGA2
Hypotrichosis 9 (2), HYPT9
Aneurysm, intracranial berry, 4 (2), ANIB4
[Uric acid concentration, serum, QTL5] (2), UAQTL5
Potocki-Shaffer syndrome (4), PSS
Leukoencephalopathy with dystonia and motor neuropathy, 613724 (3), SCP2
Hyperaldosteronism, familial, type II (2), FHII
Deafness, autosomal dominant 31 (2), DFNA31
{Asperger syndrome susceptibility 3} (2), ASPG3
Deafness, autosomal recessive 96 (2), DFNB96
Deafness, autosomal recessive 46 (2), DFNB46
Schizencephaly, 269160 (3), EMX2
Tooth agenesis, selective, 5 (2), STHAG5
[High density lipoprotein cholesterol level QTL 5] (2), HDLCQ5
Larsen-like syndrome (2), LRSL
Macular dystrophy, retinal, 3 (2), MCDR3
Bernard-Soulier syndrome, type C, 231200 (3), GP9
Hermansky-Pudlak syndrome 1, 203300 (3), HPS1
{Menarche, age at, QTL2} (2), MENAQ2
Isobutyryl-CoA dehydrogenase deficiency, 611283 (3), ACAD8
Panbronchiolitis, diffuse (2), PBLT
Gaucher disease, type I, 230800(3); Gaucher disease, type II, 230900, GBA
{Malaria, intensity of infection} (2), PFBI
Dystonia, dopa-responsive, due to sepiapterin reductase deficiency,, SPR
Muscular dystrophy, congenital, merosin-positive (2), MDCMP
Angio serpiginosum (2), AGSPX
Photoparoxysmal response 3 (2), PPR3
{Pelvic organ prolapse, susceptibility to, 2} (2), PVOP2
[High density lipoprotein cholesterol level QTL 1] (2), HDLCQ1
Chondrosarcoma, extraskeletal myxoid, 612237 (3), CSMF
Deafness, autosomal dominant 21 (2), DFNA21
CD8 deficiency, familial, 608957 (3), CD8A
Chondrocalcinosis with early-onset osteoarthritis (2), CCAL1
Deafness, autosomal recessive 33 (2), DFNB33
Mental retardation, severe, with spasticity and tapetoretinal, MRST
Retinitis pigmentosa, Y-linked (2), RPY
Brunner syndrome, 300615 (3), MAOA
{Aneurysm, intracranial berry, 10} (2), ANIB10
Lipoma (3); Leukemia, acute myeloid, 601626 (3), LPP
[High density lipoprotein cholesterol level QTL 4] (2), HDLCQ4
Pigmented nodular adrenocortical disease, primary, 4 (4), PPNAD4
Amyloidosis, Finnish type, 105120 (3), GSN
Cystinosis, nephropathic, 219800 (3); Cystinosis, ocular, CTNS
Autonomic nervous system dysfunction (3); [Novelty seeking, DRD4
Polydactyly, postaxial, type A3 (2), PAPA3
Gallbladder disease 2 (2), GBD2
[Blood group GIL], 607457 (3), AQP3
Alopecia-mental retardation syndrome 3 (2), APMR3
Factor XIIIB deficiency, 613235 (3), F13B
Mental retardation, X-linked 49 (2), MRX49
Spastic paraplegia 9, autosomal dominant (2), SPG9
Forsythe-Wakeling syndrome (2), FWS
{Stature QTL 5} (2), STQTL5
Vohwinkel syndrome with ichthyosis, 604117 (3), LOR
{Diabetes mellitus, insulin-dependent, 17} (2), IDDM17
Glaucoma, primary open angle, juvenile-onset, 2 (2), JOAG2
Charcot-Marie-Tooth neuropathy, X-linked recessive, 3 (2), CMTX3
Amyloidosis, renal, 105200 (3), LYZ
{Inflammatory bowel disease 18} (2), IBD18
Levy-Shanske syndrome (4), LVSKS
{Obesity, susceptibility to, BMIQ7} (2), BMIQ7
Myopia 12 (2), MYP12
Ulnar-mammary syndrome, 181450 (3), TBX3
Ocular albinism with sensorineural deafness (2), OASD
[Birth weight QTL4] (2), BWQTL4
{Plasmodium falciparum fever episodes QTL1} (2), PFFE1
Keratoconus 7 (2), KTCN7
Epilepsy, generalized, with febrile seizures plus, type 6 (2), GEFSP6
{Restless legs syndrome 4} (2), RLS4
{Narcolepsy 4} (2), NRCLP4
Ornithine transcarbamylase deficiency, 311250 (3), OTC
Pyloric stenosis, infantile hypertrophic, 4 (2), IHPS4
{Malignant mesothelioma, susceptibility to} (2), MMS
Acute insulin response (2), AIR
[Bone mineral density QTL 6] (2), BMND6
{Hirschsprung disease, susceptibility to, 7} (2), HSCR7
Acne inversa, familial, 1, 142690 (3), NCSTN
{Chordoma, susceptibility to} (4), CHDM
{Biliary cirrhosis, primary, 2} (2), PBC2
MEHMO syndrome (2), MEHMO
{Alkaline phosphatase, plasma level of, QTL 2} (2), ALPQTL2
Neurofibromatosis, type 2, 101000 (3); Meningioma, NF2-related,, NF2
[Body mass index QTL2] (2), BMIQ2
{Malignant hyperthermia susceptibility 3} (2), MHS3
?Zimmermann-Laband syndrome (2), ZLS
Trichorhinophalangeal syndrome, type I, 190350 (3);, TRPS1
Bartter syndrome, type 4b, digenic, 613090 (3), CLCNKA
Mean platelet volume QTL4 (2), MPVQTL4
Fundus albipunctatus, 136880 (3), RDH5
Stuttering, familial persistent, 4 (2), STUT4
Spastic paraplegia 29, autosomal dominant (2), SPG29
{Myocardial infarction, susceptibility to, 2} (2), MCI2
Wilms tumor, type 3 (2), WT3
{Dyslexia, susceptibility to, 9} (2), DYX9
Orthostatic hypotensive disorder of Streeten (2), OHDS
Mental retardation, X-linked 42 (2), MRX42
{Neuroblastoma, susceptibility to, 5} (2), NBLST5
{Inflammatory bowel disease 3} (2), IBD3
{Lung cancer susceptibility 3} (2), LNCR3
Epilepsy, partial, with pericentral spikes (2), EPPS
Biliary cirrhosis, primary, 4 (2), PBC4
Leukemia, acute pre-B-cell (2), PBX1
Panic disorder 2 (2), PAND2
{Smoking as a quantitative trait locus 1} (2), SQTL1
{Alzheimer disease 12} (2), AD12
Neutropenia, alloimmune neonatal (3), FCGR3B
{Asthma-related traits, susceptibility to, 4} (2), ASRT4
Macrothrombocytopenia, autosomal dominant, TUBB1-related, 613112 (3), TUBB1
Keratoconus 6 (2), KTCN6
Charcot-Marie-Tooth neuropathy, X-linked recessive, 2 (2), CMTX2
[Mean platelet volume QTL3] (2), MPVQTL3
Amyotrophic lateral sclerosis 7 (2), ALS7
Glaucoma 3, primary infantile, B (2), GLC3B
{Glioma susceptibility 6} (2), GLM6
{Cancer progression/metastasis} (3), FGFR4
Fabry disease, 301500 (3); Fabry disease, cardiac variant, 301500 (3), GLA
Troyer syndrome, 275900 (3), SPG20
{Systemic lupus erythematosus, susceptibility to, 13} (2), SLEB13
Cholestasis, progressive canalicular (1), VIL1
{Scoliosis, isolated, susceptibility to, 3} (2), IS3
Epidermolysis bullosa, junctional, with pyloric atresia, 226730 (3);, ITGB4
{Attention deficit-hyperactivity disorder, susceptibility to, 6} (2), ADHD6
{Autism, susceptibility to, 10} (2), AUTS10
{Psoriasis susceptibility 5} (2), PSORS5
Mental retardation, X-linked, syndromic 9 (2), MRXS9
{Hirschsprung disease, susceptibility to, 6} (2), HSCR6
Metachromatic leukodystrophy, 250100 (3), ARSA
Mental retardation, autosomal recessive 33 (2), MRT33
Leukemia/lymphoma, B-cell, 2 (3), BCL2
Spastic paraplegia 26, autosomal recessive (2), SPG26
Macular dystrophy, North Carolina type (2), MCDR1
{Fatty liver disease, nonalcoholic, susceptibility to, 2} (2), NAFLD2
?Thrombophilia due to decreased release of tissue plasminogen (1), THPH9
{Leukemia, acute lymphoblastic, susceptibility to, 2} (2), ALL2
{Basal cell carcinoma, susceptibility to, 2} (2), BCC2
CPT deficiency, hepatic, type IA, 255120 (3), CPT1A
MASP2 deficiency, 613791 (3), MASP2
Macrostomia (2), MACST
Bleeding disorder, east Texas type (2), BDET
{Biliary cirrhosis, primary, 3} (2), PBC3
{Major affective disorder-8, susceptibility to} (2), MAFD8
[Blood group, XG system] (3), XG
?Hairy ears, Y-linked (2), HEY
{Kawasaki disease, susceptibility to}, 611775 (3), ITPKC
Bazex syndrome (2), BZX
Chromosome 8p11 myeloproliferative syndrome (4), SCLL
Deafness, autosomal dominant 49 (2), DFNA49
{Celiac disease, susceptibility to, 8} (2), CELIAC8
[Dopamine-beta-hydroxylase activity levels, plasma] (3);, DBH
{Melanoma, uveal, susceptibility to, 2} (2), UVM2
{Vitamin B6 plasma level QTL 1} (2), B6QTL1
Transient erythroblastopenia of childhood (2), TEC
{Diabetes mellitus, insulin-dependent, 7} (2), IDDM7
Spastic paraplegia 36, autosomal dominant (2), SPG36
Retinitis pigmentosa 54, 613428 (3), C2orf71
Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase, GPI
{Prostate cancer, hereditary, 15} (2), HPC15
{Celiac disease, susceptibility to, 11} (2), CELIAC11
McArdle disease, 232600 (3), PYGM
Squamous cell carcinoma, head and neck, somatic, 275355 (3), ING1
{Hypospadias 4, X-linked, susceptibility to} (2), HYSP4
{Inflammatory bowel disease 6} (2), IBD6
{Pulmonary function} (2), PLF
Factor X deficiency, 227600 (3), F10
Deafness, autosomal recessive 45 (2), DFNB45
Tukel syndrome (2), TUKLS
Anisomastia (2), ANMA
Optic atrophy 5 (2), OPA5
Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis,, SARS2
{Psoriasis susceptibility 12} (2), PSORS12
Amyotrophic lateral sclerosis 3 (2), ALS3
Porphyria variegata, 176200 (3), PPOX
Majeed syndrome, 609628 (3), LPIN2
{Dyslexia, susceptibility to, 8} (2), DYX8
Epilespy, generalized, with febrile seizures plus, type 8 (2), GEFSP8
Obesity, adrenal insufficiency, and red hair due to POMC deficiency,, POMC
Hyperlipidemia, combined, 2 (2), HYPLIP2
ApoA-I and apoC-III deficiency, combined (3);, APOA1
[Body mass index QTL6] (2), BMIQ6
von Hippel-Lindau syndrome, 193300 (3); Renal cell carcinoma,, VHL
Glaucoma 1D, primary open angle (2), GLC1D
Cousin syndrome, 260660 (3), TBX15
Mental retardation, autosomal recessive 35, 615162 (3), MRT35
Chromosome 22q11.2 microduplication syndrome (4), DUP22q11.2
Rajab syndrome (2), RJBS
Nephropathy, progressive, with deafness (2), NEDE
{Stature QTL 12} (2), STQTL12
Reticular dysgenesis, 267500 (3), AK2
Orofacial cleft 14 (2), OFC14
Pseudohyperkalemia, familial, 2, due to red cell leak (2), PSHK2
{Stature QTL 22} (2), STQTL22
{Basal cell carcinoma, susceptibility to, 4} (2), BCC4
Renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3);, MET
{Mycobacterium tuberculosis, susceptibility to, 3} (2), MTBS3
Deafness, autosomal recessive 26 (2), DFNB26
Hereditary motor and sensory neuropathy V (2), HMSN5
[Bone size quantitative trait locus 3] (2), BSZQTL3
Alzheimer disease-7 (2), AD7
Deafness, autosomal dominant 53 (2), DFNA53
Exostoses, multiple, type 1, 133700 (3); Chondrosarcoma, 215300 (3), EXT1
Glaucoma 1, open angle, N (2), GLC1N
{Stature QTL 14} (2), STQTL14
Vertigo, benign recurrent, 2 (2), BRV2
Hyperhidrosis palmaris et plantaris (2), HHPP
Thyroid carcinoma, nonmedullary, 1 (2), NMTC1
Mental retardation, X-linked, syndromic, Chudley-Schwartz type, (2), MRXSCS
Aneurysm, intracranial berry, 1 (2), ANIB1
{Lung cancer susceptibility} (2), LNCR1
{Hypertension, essential, salt-sensitive}, 145500 (3), ADD1
Peripheral arterial occlusive disease 1 (2), PAOD1
Bare lymphocyte syndrome, type II, complementation group D, 209920, RFXAP
Medulloblastoma, 155255 (3); Basal cell carcinoma, somatic, 605462, PTCH2
{Migraine, familial typical, susceptibility to, 2} (2), MGR2
Abdominal obesity-metabolic syndrome (2), AOMS2
{Cardiac conduction defect, susceptibility to}, 115080 (3), AKAP10
?Hepatocellular carcinoma (1), LCO
Immunoglobulin A deficiency (2), IGAD1
Otosclerosis 10 (2), OTSC10
{Inflammatory bowel disease 16} (2), IBD16
Phosphorylase kinase deficiency of liver and muscle, autosomal, PHKB
{Deafness, nonsyndromic, modifier 1} (2), DFNM1
Microphthalmia with cataract 1 (2), MCOPCT1
Cystathioninuria, 219500 (3); Homocysteine, total plasma, elevated, CTH
[IgE, elevated level of], 147050 (3); Immunodeficiency, primary,, IL21R
{Restless legs syndrome 2} (2), RLS2
{Diabetes mellitus, insulin-dependent, 15} (2), IDDM15
Ichthyosis, congenital, autosomal recessive 7, 615022 (3), ARCI7
{Glioma susceptibility 5} (2), GLM5
{Inflammatory bowel disease 23} (2), IBD23
{Diabetes mellitus, insulin-dependent, 13} (2), IDDM13
{Diabetes mellitus, insulin-dependent, 4} (2), IDDM4
Epilepsy, generalized, with febrile seizures plus, type 4 (2), GEFSP4
Glaucoma 1, open angle, M (2), GLC1M
Aural atresia, congenital (2), CAA
{Multiple sclerosis, susceptibility to, 4} (2), MS4
Homocysteine plasma level (2), NNMT
{Restless legs syndrome, susceptibility to, 8} (2), RLS8
Stuttering, familial persistent, 1 (2), STUT1
[Blood group, ABO system], 616093 (3), ABO
Pulmonary disease, chronic obstructive, severe early-onset (2), COPD
?EEC syndrome-1 (2), EEC1
{Dyslexia, susceptibility to, 5} (2), DYX5
Retinitis pigmentosa 29 (2), RP29
Mental retardation, autosomal recessive 25 (2), MRT25
Enuresis, nocturnal, 2 (2), ENUR2
Galactokinase deficiency with cataracts, 230200 (3), GALK1
{Inflammatory bowel disease 12} (2), IBD12
{Leukemia, chronic lymphocytic susceptibility to, 5} (2), CLLS5
Xanthinuria, type I, 278300 (3), XDH
Ulna and fibula, absence of, with severe limb deficiency, 276820 (3);, WNT7A
6-mercaptopurine sensitivity, 610460 (3), TPMT
Eosinophilia, familial (2), EOS
{Coronary heart disease, susceptibility to, 2} (2), CHDS2
Spastic paraplegia 37, autosomal dominant (2), SPG37
Arthrogryposis, distal, type 2A, 193700 (3); Arthrogryposis, distal,, MYH3
Retinitis pigmentosa 22 (2), RP22
Breast cancer (1), BCPR
{Psoraisis susceptibility 9} (2), PSORS9
{Asperger syndrome susceptibility 1} (2), ASPG1
{Diabetes mellitus, type 2, susceptiblity to}, 125853 (3), MTNR1B
Aspartylglucosaminuria, 208400 (3), AGA
{Colorectal cancer, susceptibility to, 5} (2), CRCS5
{Diabetes mellitus, insulin-dependent, 11} (2), IDDM11
{Menopause, natural, age at, QTL2} (2), MENOQ2
Microcephaly, mental retardation, and distinctive facies, with, MMRFCGU
{Schizophrenia, susceptibility to}, 181500 (3); {Panic disorder,, COMT
Myopia 14 (2), MYP14
Amyotrophic lateral sclerosis 5, juvenile recessive (2), ALS5
Deafness, autosomal recessive 71 (2), DFNB71
Stickler syndrome, type I, 108300 (3); Kniest dysplasia, 156550 (3);, COL2A1
{Graves disease, susceptibility to, 1} (2), GRD1
Deafness, autosomal dominant 33 (2), DFNA33
Leukemia, acute promyelocytic, NPM/RARA type (3); Leukemia, acute, NPM1
Brachydactyly, type A1, B (2), BDA1B
Hypercholanemia, familial, 607748 (3), BAAT
Acromegaloid features, overgrowth, cleft palate, and hernia (2), AOCH
Major depressive disorder 2, 608516 (2), MDD2
{Stature QTL 24} (2), STQTL24
Myopia 10 (2), MYP10
{Spondyloarthropathy, susceptibility to, 2} (2), SPDA2
Hypospadias 3, autosomal (2), HYSP3
{Nonsmall cell lung cancer} (2), TSG11
{Epilepsy, juvenile myoclonic, susceptiblity to, 9} (2), EJM9
?Mental retardation, X-linked, syndromic 12 (2), MRXS12
{Coronary heart disease, susceptibility to, 3} (2), CHDS3
Cone dystrophy, progressive X-linked, 2 (2), COD2
Male germ cell tumor (2), MGCT
{Kala-azar, susceptibility to, 3} (2), KAZA3
{Asperger syndrome susceptibility 2} (2), ASPG2
[Bone mineral density QTL 3] (2), BMND3
{Schistosoma mansoni infection, susceptibility/resistance to} (2), SM1
Otosclerosis 2 (2), OTSC2
?Fetal hydantoin syndrome (1); Diphenylhydantoin toxicity (1);, EPHX1
Brugada syndrome 4, 611876 (3), CACNB2
Mental retardation, autosomal recessive, 8 (2), MRT8
Holt-Oram syndrome, 142900 (3), TBX5
{Macroglobulinemia, Waldenstrom, susceptibility to, 2} (2), WM2
Neurodegeneration due to cerebral folate transport deficiency,, FOLR1
CHILD syndrome, 308050 (3); CK syndrome, 300831 (3), NSDHL
Hypertension with brachydactyly (2), HTNB
[Lean body mass QTL 1] (2), LBMQTL1
Dystonia-15, myoclonic (2), DYT15
3-methylglutaconic aciduria, type I, 250950 (3), AUH
Bardet-Biedl syndrome 2, 615981 (3), BBS2
{Stature QTL 15} (2), STQTL15
Ehlers-Danlos syndrome, type VIII (2), EDS8
{Vitiligo-associated multiple autoimmune disease susceptiblity 6} (2), VAMAS6
Synpolydactyly 3 (2), SPD3
Obesity, severe, 601665 (3), SIM1
[Respiratory rhythmicity in sleep] (2), RRIS
Mental retardation, X-linked, with short stature (2), MRSS
Aneurysmal bone cysts (2), ANBC
{Multiple sclerosis, susceptibility to, 2} (2), MS2
Growth retardation with deafness and mental retardation due to, IGF1
{Schizophrenia 10} (2), SCZD10
Glycine N-methyltransferase deficiency, 606664 (3), GNMT
Temple syndrome (4), TEMPS
{Intelligence QTL1} (2), INTLQ1
[Birth weight QTL 2] (2), BWQTL2
{Diabetes mellitus, insulin-dependent, 18} (2), IDDM18
Glycogen storage disease 0, liver, 240600 (3), GYS2
Dyschromatosis universalis hereditaria 2 (2), DUH2
{Stature QTL 11} (2), STQTL11
Thalassemia, delta- (3); Thalassemia due to Hb Lepore (3), HBD
Fucosidosis, 230000 (3), FUCA1
Facial paresis, hereditary congenital, 2 (2), HCFP2
RIDDLE syndrome, 611943 (3), RNF168
Cone-rod dystrophy 17 (2), CORD17
?Melkersson-Rosenthal syndrome (2), MROS
Muscular dystrophy with rimmed vacuoles (2), MDRV
C1r/C1s deficiency, combined, 216950 (1), C1R
Aicardi syndrome (2), AIC
Exocrine pancreatic insufficiency, dyserythropoietic anemia, and, COX4I2
Glycogen storage disease II, 232300 (3), GAA
{Inflammatory bowel disease 9} (2), IBD9
Narcolepsy 3 (2), NRCLP3
{Autism susceptibility 11} (2), AUTS11
Retinitis pigmentosa 32 (2), RP32
Polymicrogyria, bilateral occipital (2), BOP
{Inflammatory bowel disease 7} (2), IBD7
Corneal dystrophy, endothelial, X-linked (2), XECD
{Systemic lupus erythematosus, susceptibility to, 7} (2), SLEB7
{Menopause, natural, age at, QTL4} (2), MENOQ4
{Hypertension, essential, susceptibility to, 3}, 145500 (2), HYT3
Usher syndrome, type 1H (2), USH1H
Ectodermal dysplasia-syndactyly syndrome 2 (2), EDSS2
?Antiphospholipid syndrome, familial (2), ATPLS
C8 deficiency, type I, 613790 (3), C8A
{Systemic lupus erythematosus with nephritis, susceptibility to, 1}, SLEN1
Aneurysm, intracranial berry, 2 (2), ANIB2
Holoprosencephaly-8 (2), HPE8
?Retinal cone dystrophy-1 (2), RCD1
Pyloric stenosis, infantile hypertrophic, 5 (2), IHPS5
{Retinal disease in Usher syndrome type IIA, modifier of}, 276901, PDZD7
Wolf-Hirschhorn syndrome (4), WHS
{Psoriasis susceptibility 6} (2), PSORS6
C1s deficiency, 613783 (3), C1S
Lactase persistence/nonpersistence, 223100 (3), MCM6
Glaucoma 1C, primary open angle (2), GLC1C
CDAGS syndrome (2), CDAGS
Developmental dysplasia of the hip 1 (2), DDH1
Pyruvate carboxylase deficiency, 266150 (3), PC
Vestibulopathy, familial (2), BPPV
Choroidal dystrophy, central areolar 1 (2), CACD1
{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3), PRPH
Atrial fibrillation, familial, 8 (2), ATFB8
Ceroid lipofuscinosis, neuronal, 5, 256731 (3), CLN5
Diamond-Blackfan anemia 2 (2), DBA2
Cardiomyopathy, dilated, 1DD, 613172 (3), RBM20
Osteopetrosis, autosomal recessive 3, with renal tubular acidosis,, CA2
{Inflammatory bowel disease 22} (2), IBD22
Trifunctional protein deficiency, 609015 (3), HADHB
Platelet PLC beta-2 deficiency (1), PLCB2
{Asperger syndrome susceptibility 4} (2), ASPG4
Pseudovaginal perineoscrotal hypospadias, 264600 (3), SRD5A2
Deafness, autosomal recessive 83 (2), DFNB83
Deafness, autosomal recessive 66 (2), DFNB66
Ellis-van Creveld syndrome, 225500 (3); Weyers acrodental dysostosis,, EVC
[Cinnamon odor, pleasantness of] (2), CINN
?Retinitis pigmentosa, X-linked recessive, 6 (2), RP6
[Bone mineral density QTL 10] (2), BMND10
Carpenter syndrome, 201000 (3), RAB23
[Fasting insulin level quantitative trait locus 1] (2), FIQTL1
{Lumbar disc disease, susceptibility to}, 603932 (3), CILP
Microtia with nasolacrimal duct imperforation and eye coloboma (1), MNDEC
?Neuroblastoma (1), TP73
?Keratoderma, palmoplantar, punctate type 3 (2), PPKP3
{Systemic lupus erthematosus, susceptibility to, 15} (2), SLEB15
{Diabetes mellitus, insulin-dependent, 6} (2), IDDM6
Mental retardation, X-linked 52 (2), MRX52
{Coronary artery disease, susceptibility to} (1); [LPA deficiency,, LPA
Argininosuccinic aciduria, 207900 (3), ASL
Mental retardation, X-linked 84 (2), MRX84
Microphthalmia with coloboma 2 (2), MCOPCB2
{Menarche, age at, QTL3} (2), MENAQ3
Bardet-Biedl syndrome 5, 615983 (3), BBS5
{Systemic lupus erythematosus, susceptibility to, 14} (2), SLEB14
{Parkinson disease 12} (2), PARK12
{Beryllium disease, chronic, susceptibility to} (3), HLA-DPB1
Deafness, autosomal dominant 7 (2), DFNA7
Porphyria, congenital erythropoietic, 263700 (3), UROS
{Coronary artery disease, susceptibility to} (3), PON2
Charcot-Marie-Tooth disease, dominant intermediate A (2), CMTDIA
Ptosis, hereditary congenital, 1 (2), PTOS1
Mungan syndrome (2), MGS
{Hepatitis B virus, susceptibility to}, 610424 (3), IFNAR2
Epilepsy, childhood absence, 1 (2), ECA1
{Psoriasis susceptibility 4} (2), PSORS4
Carnosinemia (2), CNSN
Mammary-digital-nail syndrome (2), MDNS
[Alpha-actinin-3 deficiency] (3); [Sprinting performance] (3), ACTN3
Severe combined immunodeficiency due to ADA deficiency, 102700 (3);, ADA
Otosclerosis 8 (2), OTSC8
{Restless legs syndrome 7} (2), RLS7
{Stature QTL 20} (2), STQTL20
Mental retardation, autosomal recessive 31 (2), MRT31
[Rh-negative blood type] (3), RHD
Vesicoureteral reflux 5 (2), VUR5
Jacobsen syndrome (4), JBS
{Alkaline phosphatase, plasma level of, QTL4} (2), ALPQTL4
[Glutaric aciduria III], 231690 (3), C7orf10
Otosclerosis 7 (2), OTSC7
{Parkinson disease 16} (2), PARK16
Cayler cardiofacial syndrome (2), ACF
{Prostate cancer, hereditary, 5}, 176807 (2), HPC5
{Spinal muscular atrophy, type III, modifier of}, 253400 (3), SMN2
Erythrocytosis due to bisphosphoglycerate mutase deficiency,, BPGM
Muscle glycogenosis, 300559 (3), PHKA1
Deafness, autosomal recessive 55 (2), DFNB55
Branchiootic syndrome 2 (2), BOS2
{Opioid dependence, susceptibility to, 1} (2), ODS1
Isovaleric acidemia, 243500 (3), IVD
Oculomotor apraxia, congenital, Cogan-type (2), COMA
{Melanoma, cutaneous malignant, 7} (2), CMM7
Spinocerebellar ataxia, autosomal recessive 12 (2), SCAR12
{Otitis media, susceptibility to} (2), OMS
Transaldolase deficiency, 606003 (3), TALDO1
Paget disease of bone, 602080 (2), PDB4
Fucosyltransferase 6 deficiency, 613852 (3), FUT6
{Systemic lupus erythematosus with nephritis, susceptibility to, 2}, SLEN2
Orofacial cleft-2 (2), OFC2
Ectodermal dysplasia 6, hair/nail type (2), ECTD6
{Endometriosis, susceptibility to, 1} (2), ENDO1
Endometrial carcinoma, somatic (3), MSH3
{Podoconiosis, susceptibility to} (2), PDCOS
FG syndrome 5 (2), FGS5
Sulfite oxidase deficiency, 272300 (3), SUOX
{Stature QTL 21} (2), STQTL21
Polycystic kidney disease, adult type I, 173900 (3), PKD1
Mitochondrial complex I deficiency due to ACAD9 deficiency, 611126, ACAD9
{Dermatitis, atopic, susceptibility to, 4} (2), ATOD4
[Tuberculin skin test reactivity, absence of] (2), TST1
{Leukemia, chronic lymphocytic, susceptibility to, 1} (2), CLLS1
{Coronary heart disease, susceptibility to} (2), CHDS1
Spinocerebellar ataxia 32 (2), SCA32
Deafness, autosomal recessive 20 (2), DFNB20
{Prostate cancer, hereditary, 10} (2), HPC10
[AMP deaminase deficiency, erythrocytic], 612874 (3), AMPD3
{Hypercholesterolemia, familial, due to LDLR defect, modifier of},, EPHX2
Mental retardation, X-linked, syndromic 17 (2), MRXS17
{Neuroblastoma, susceptibility to, 4} (2), NBLST4
Schindler disease, type I, 609241 (3); Kanzaki disease, 609242 (3);, NAGA
[C-reactive protein QTL] (2), CPROTQ
Methylmalonyl-CoA epimerase deficiency, 251120 (3), MCEE
{Melanoma, uveal, susceptibility to, 1} (2), UVM1
Hernia, congenital diaphragmatic 2 (2), DIH2
[Body mass index QTL1] (2), BMIQ1
Ciliary dyskinesia, primary, 8 (2), CILD8
[Handedness] (2), HSR
Chromosome 18q deletion syndrome (4), DEL18q
Spinocerebellar ataxia 12, 604326 (3), PPP2R2B
{Dyslexia, susceptibility to, 3} (2), DYX3
Fructose intolerance, 229600 (3), ALDOB
Split-hand/foot malformation 5 (2), SHFM5
Spastic paraplegia 25, autosomal recessive (2), SPG25
Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 (3), MC2R
?Stomatocytosis I, 185000 (1), EPB72
Leukemia, acute myelogenous, 601626 (3), GMPS
Schizophrenia, neurophysiologic defect in (2), CHRNA7
Thyroid carcinoma, nonmedullary, with cell oxyphilia (2), TCO
Spinocerebellar ataxia, X-linked 5 (2), SCAX5
Goldberg-Shprintzen megacolon syndrome, 609460 (3), KIAA1279
Deafness, autosomal dominant 30 (2), DFNA30
Muscular dystrophy, congenital, 1B (2), MDC1B
Myopia 15 (2), MYP15
Dystonia-17, primary torsion (2), DYT17
Left ventricular noncompaction 2 (2), LVNC2
Panic disorder 3 (2), PAND3
{Diabetes mellitus, insulin-dependent, 21} (2), IDDM21
{Asthma-related traits, susceptibility to, 6} (2), ASRT6
Weill-Marchesani-like syndrome, 613195 (3), ADAMTS17
{Narcolepsy 5} (2), NRCLP5
[Creatine kinase, brain type, ectopic expression of] (2), CKBE
{Macroglobulinemia, Waldenstrom, susceptibility to, 1} (2), WM1
Hypothyroidism, congenital, due to thyroid dysgenesis or, PAX8
Spermatogenic failure, X-linked, 2 (2), SPGFX2
Congenital heart defects, multiple types, 3 (2), CHDT3
{Hypertension, essential, susceptibility to, 1}, 145500 (2), HYT1
Major depressive disorder 1, 608516 (2), MDD1
Mental retardation, autosomal recessive 30 (2), MRT30
Complex I, mitochondrial respiratory chain, deficiency of, 252010 (3), NDUFS6
Aortic aneurysm, familial abdominal, 4 (2), AAA4
Febrile seizures, familial, 5 (2), FEB5
Rhabdomyolysis, cerivastatin-induced (3), CYP2C8
Hypertensive nephropathy (2), HNP1
Wilms tumor, type 4 (2), WT4
Spastic paraplegia 16, X-linked, complicated (2), SPG16
{Glioma susceptibility 7} (2), GLM7
[Bone mineral density QTL 2] (2), BMND2
Lymphoma/leukemia, B-cell, variant (1), FVT1
{Major affective disorder-9, susceptibility to} (2), MAFD9
Corpus callosum, agenesis of, with mental retardation, ocular, IGBP1
{Obesity, susceptibility to, BMIQ8} (2), BMIQ8
Aneurysm, intracranial berry, 11 (2), ANIB11
Hypoproteinemia, hypercatabolic, 241600 (3), B2M
{Schizophrenia 12}, 181500 (2), SCZD12
{Epilepsy, idiopathic generalized, susceptibility to 4} (2), EIG4
Ciliary dyskinesia, primary, 14, 613807 (3), CCDC39
Anosmia, isolated congenital (2), ANIC
{Diabetes mellitus, insulin-dependent, 8} (2), IDDM8
Alcohol sensitivity, acute, 610251 (3); {Hangover, susceptibility, ALDH2
{Stature QTL 6} (2), STQTL6
Hemolytic anemia due to phosphofructokinase deficiency (1), PFKL
Dementia, Lewy body, 127750 (3), SNCB
Trichilemmal cyst 1 (2), TRICY1
Waardenburg syndrome, type 2B (2), WS2B
Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, 612350 (3), SLC39A13
?Preauricular fistulae, congenital (2), PAFC
Miyoshi muscular dystrophy 2 (2), MMD2
Epilepsy, X-linked, with variable learning disabilities and, SYN1
[Fasting plasma glucose level QTL 1] (2), FGQTL1
Galactosemia, 230400 (3), GALT
Mental retardation, autosomal recessive 28 (2), MRT28
{Graves disease, susceptibility to, 2} (2), GRD2
[Fasting plasma glucose level QTL 4] (2), FGQTL4
X inactivation, familial skewed, 2 (2), SXI2
{Coronary artery spasm 1, susceptibility to} (3); {Alzheimer disease,, NOS3
Microphthalmia with coloboma 1 (2), MCOPCB1
{Otosclerosis 4} (2), OTSC4
{Systemic lupus erythematosus with nephritis, susceptibility to, 3}, SLEN3
Tremor, hereditary essential, 3 (2), ETM3
Glaucoma 3, primary congenital, C (2), GLC3C
Exostoses, multiple, type 3 (2), EXT3
[Urate oxidase deficiency] (1), UOX
Parasomnia, sleepwalking type (2), PSMNSW
Pycnodysostosis, 265800 (3), CTSK
Alopecia-mental retardation syndrome 2 (2), APMR2
Alpha-ketoglutarate dehydrogenase deficiency, 203740 (1), OGDH
?Coffin-Siris syndrome (2), CSS
Megaloblastic anemia-1, Norwegian type, 261100 (3), AMN
{Hypertension, essential, susceptibility to, 4}, 145500 (2), HYT4
Leukemia/lymphoma, B-cell, 3 (2), BCL3
Febrile seizures, familial, 1 (2), FEB1
{Adiponectin, serum level of, QTL4} (2), ADIPQTL4
?Craniofacioskeletal syndrome (2), CFSS
Tourette syndrome (2), GTS
Orofacial cleft 9 (2), OFC9
Mental retardation, X-linked, syndromic, Martin-Probst type (2), MRXSMP
Colorectal cancer, somatic, 114500 (3);, BAX
Hemorrhagic destruction of the brain, subependymal calcification,, JAM3
[Sex hormone-binding blobulin circulating level QTL 1] (2), SXGQTL1
Myopia-1 (2), MYP1
[Uric acid concentration, serum, QTL6] (2), UAQTL6
{Aneurysm, familial abdominal 3} (2), AAA3
{Celiac disease, susceptibility to, 12} (2), CELIAC12
{Inflammatory bowel disease 15} (2), IBD15
Keratoderma, palmoplantar, punctate type IB (2), PPKP1B
Insulin-like growth factor I, resistance to, 270450 (3), IGF1R
{Epilepsy, idiopathic generalized, susceptibility to, 2} (2), EIG2
Small-cell cancer of lung (2), SCLC1
Dystonia 21 (2), DYT21
[Gamma-glutamyltransferase, familial high serum] (2), GGT2
{Systemic lupus erythematosus, susceptibility to, 4} (2), SLEB4
Obesity, autosomal dominant, 601665 (3), MC4R
Eosinophil peroxidase deficiency, 261500 (3), EPX
{Hodgkin disease susceptibility, pseudoautosomal} (2), HDPA
Deafness, autosomal dominant 18 (2), DFNA18
{Inflammatory bowel disease 8} (2), IBD8
[Body mass index QTL14] (2), BMIQ14
{Psoriasis susceptibility 11} (2), PSORS11
{Mycobacerium tuberculosis, susceptibility, X-linked} (2), MTBSX
Epilepsy, juvenile myoclonic 3 (2), EJM3
Alzheimer disease 8, 104300 (2), AD8
{Schizophrenia, susceptibility to, 13} (2), SCZD13
Forebrain defects (3), TDGF1
Mental retardation, X-linked 50 (2), MRX50
{Colorectal cancer, susceptibility to, 2} (2), CRCS2
Pierre Robin syndrome (2), PRBNS
Homocystinuria, B6-responsive and nonresponsive types, 236200 (3);, CBS
Cataract 29, coralliform (2), CTRCT29
{Systemic lupus erythematosus, susceptibility to, 5} (2), SLEB5
Myeloperoxidase deficiency, 254600 (3); {Alzheimer disease,, MPO
Nystagmus 3, congenital, autosomal dominant (2), NYS3
{Stature QTL 3} (2), STQTL3
{Stature QTL 10} (2), STQTL10
{Colorectal cancer, susceptibility to, 8} (2), CRCS8
{Hypertension, essential, susceptibility to, 5}, 145500 (2), HYT5
Mental retardation, X-linked 14 (2), MRX14
Spastic paraplegia 32, autosomal recessive (2), SPG32
{Diabetes mellitus, insulin-dependent, 3} (2), IDDM3
{Menarche, age at, QTL} (2), MENAQ1
Keratolytic winter erythema (2), KWE
{Restless legs syndrome 3} (2), RLS3
Spastic paraplegia 23 (2), SPG23
Spastic paraplegia 38, autosomal dominant (2), SPG38
Myopia 16 (2), MYP16
Hypertelorism, preauricular sinus, punctal pits, and deafness (2), HPPD
{?Schizophrenia}, 181500 (2), SCZD2
Narcolepsy 2 (2), NRCLP2
Periventricular nodular heterotopia 5 (4), PVNH5
Deafness, autosomal recessive 51 (2), DFNB51
Dopamine receptor D2, reduced brain density of (3), ANKK1
Bartter syndrome, type 4a, 602522 (3); Sensorineural deafness with, BSND
{Pulmonary hypertension, chronic thromboembolic, without deep vein, CTEPH1
Bartter syndrome, type 3, 607364 (3); Bartter syndrome, type 4b,, CLCNKB
?Phosphoenolpyruvate carboxykinase-1, cytosolic, deficiency, 261680, PCK1
Photoparoxysmal response 2 (2), PPR2
Alpha-methylacetoacetic aciduria, 203750 (3), ACAT1
Welander distal myopathy (2), WDM
Leukemia, acute myeloblastic (3), ARNT
{Lung cancer susceptibility 4} (2), LNCR4
Preeclampsia/eclampsia 2 (2), PEE2
Pyridoxamine 5'-phosphate oxidase deficiency, 610090 (3), PNPO
Specific language impairment QTL, 1 (2), SLI1
Factor XI deficiency, autosomal recessive, 612416 (3); Factor XI, F11
[Tuberculin skin test reactivity QTL] (2), TST2
?Paget disease of bone (2), PDB
Mental retardation, autosomal recessive 19 (2), MRT19
Myoglobinuria, acute recurrent, autosomal recessive, 268200 (3), LPIN1
Deafness, autosomal recessive 36, 609006 (3); Deafness, neurosensory,, ESPN
?Diabetes mellitus, insulin-dependent, neonatal (2), PBCA
{Inflammatory bowel disease 4} (2), IBD4
Spastic paraplegia 34, X-linked (2), SPG34
Testicular germ cell tumor (2), TGCT1
Mental retardation, X-linked 95 (2), MRX95
Narcolepsy 6 (2), NRCLP6
Optic atrophy 6 (2), OPA6
Febrile seizures, familial, 6 (2), FEB6
{Adiponectin, serum level of, QTL5] (2), ADIPQTL5
?Progesterone resistance, 264080 (2), PGR
Anemia, hypochromic microcytic, 206100 (3), NRAMP2
Sickle cell anemia, 603903 (3); Thalassemias, beta-, 613985 (3);, HBB
Leukoencephaly with vanishing white matter, 603896 (3);, EIF2B4
Severe combined immunodeficiency due to IL2 deficiency (1), IL2
Cardiomyopathy, dilated, 1H (2), CMD1H
{Diabetes, type 2, susceptibility to}, 125853 (3), GPD2
Deafness, autosomal dominant 58 (2), DFNA58
{Parkinson disease 3} (2), PARK3
Polycystic kidney disease 2, 613095 (3), PKD2
Spinocerebellar ataxia 25 (2), SCA25
Keratoconus 2 (2), KTCN2
{Dermatitis, atopic, susceptibility to, 1} (2), ATOD1
Nail disorder, nonsyndromic congenital, 9 (2), NDNC9
{Migraine with aura, susceptibility to, 9} (2), MGR9
{Autism, susceptibility to, 9} (2), AUTS9
Methylmalonic aciduria, vitamin B12-responsive, due to defect in, MMAB
{Prostate cancer, hereditary, 11} (2), HPC11
Lipoid adrenal hyperplasia, 201710 (3), STAR
Vesicoureteral reflux 7 (2), VUR7
{Menopause, natural, age at, QTL1} (2), MENOQ1
Cardiomyopathy, dilated, 1Q (2), CMD1Q
Spondyloepiphyseal dysplasia tarda, autosomal dominant (2), SPDT
{Diabetes mellitus, insulin-dependent, 23} (2), IDDM23
Glaucoma 1, open angle, P (4), GLC1P
Kondoh syndrome (2), KONDS
[Blood group, Rhesus], 111690 (3); Rh-null disease, amorph type, RHCE
{Prostate cancer, hereditary, 14} (2), HPC14
Leukemia, acute promyelocytic, STAT5B/RARA type (3); Growth hormone, STAT5B
Mental retardation, X-linked 77 (2), MRX77
Orofacial cleft 12 (2), OFC12
Gastroesophageal reflux (2), GER
Mucolipidosis III gamma, 252605 (3), GNPTAG
{Autism susceptibility 7} (2), AUTS7
Myopia 8 (2), MYP8
Hyperparathyroidism 3 (2), HRPT3
{Coronary heart disease, susceptibility to, 4} (2), CHDS4
Epilepsy, nocturnal frontal lobe, type 2 (2), ENFL2
Sebaceous tumors, somatic (3), LEF1
Myasthenia gravis with thymus hyperplasia (2), MYAS1
Bardet-Biedl syndrome 7, 615984 (3), BBS7
Specific language impairment QTL, 3 (2), SLI3
Metaphyseal chondrodysplasia, Schmid type, 156500 (3), COL10A1
Vesicoureteral reflux 6 (2), VUR6
{Hypertension, essential, susceptibility to}, 145500 (3), GNB3
Aneurysm, intracranial berry, 7 (2), ANIB7
Mental retardation, X-linked 89 (2), MRX89
{Anorexia nervosa, susceptibility to, 1} (2), ANON1
Myelodysplasia syndrome-1 (3), MDS1
Insulinoma (1), ITS
{Celiac disease, susceptibility to, 7} (2), CELIAC7
Spastic paraplegia 14, autosomal recessive (2), SPG14
Microhydranencephaly (2), MHAC
Wegener granulomatosis (2), WG
3-beta-hydroxysteroid dehydrogenase, type II, deficiency, 201810 (3), HSD3B2
[Anhaptoglobinemia], 614081 (3); [Hypohaptoglobinemia], 614081 (3), HP
Alzheimer disease 6, 104300 (2), AD6
Turner syndrome-associated neurocognitive phenotype (2);, VSPA
{Alzheimer disease 9, late onset, susceptibility to}, 104300 (2), AD9
Usher syndrome, type 1E (2), USH1E
Mental retardation, autosomal recessive, 4 (2), MRT4
Cushing syndrome, ACTH-independent adrenal, somatic, 615830 (3), PRKACA
Polydactyly, postaxial, type A5 (2), PAPA5
Dermoids of cornea (2), CND
Chronic granulomatous disease, autosomal, due to deficiency of CYBA,, CYBA
Krabbe disease, 245200 (3), GALC
{Restless legs syndrome 5} (2), RLS5
[Blood group, Stoltzfus system] (2), SF
{Fatty liver disease, nonalcoholic, susceptibility to, 1} (2), NAFLD1
Fetal hemoglobin quantitative trait locus 4 (2), HBFQTL4
Mean platelet volume QTL6 (2), MPVQTL6
Mental retardation, X-linked 2 (2), MRX2
{Hypertriglyceridemia, susceptibility to} (2), HTGS
Biliary cirrhosis, primary, 5 (2), PBC5
Deafness, autosomal recessive 68 (2), DFNB68
{Rheumatoid arthritis, systemic juvenile, susceptibility to},, MIF
{Leprosy, susceptiblity to, 6} (2), LPRS6
Arrhythmogenic right ventricular dysplasia 4 (2), ARVD4
{Pelvic organ prolapse, susceptibility to, 1} (2), PVOP1
{Kala-azar, susceptibility to, 2} (2), KAZA2
Renal cell carcinoma, clear cell, somatic, 144700 (3), OGG1
Telangiectasia, hereditary hemorrhagic, type 4 (2), HHT4
{Diabetes, type 1, susceptibility to}, 222100 (2), ITPR3
Leigh syndrome, due to COX deficiency, 256000 (3), SURF1
[Cholesterol level QTL 2] (2), CLQTL2
Goiter, multinodular, 3 (2), MNG3
Periodontitis, aggressive, 2 (2), PDON2
{Bulimia nervosa, susceptibility to} (2), BULN
{Kala-azar, susceptibility to, 1} (2), KAZA1
Mental retardation, autosomal recessive 29 (2), MRT29
{Mycobacterium tuberculosis, susceptibility to, 2} (2), MTBS2
Tyrosinemia, type III, 276710 (3); Hawkinsinuria, 140350 (3), HPD
?Heterotaxy, visceral, 3, autosomal (2), HTX3
{Stature QTL 19} (2), STQTL19
Hemifacial microsomia (2), HFM
{Osteoporosis, susceptibility to}, 166710 (3), RIL
{Speech-sound disorder} (2), SSD
Burkitt lymphoma, 113970 (3), MYC
